Genomic Health (GHDX) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/29/2026
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- HF Sinclair plans to spin off lubricants unit, close Canadian refinery
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- S&P 500 ends higher as investors await tech earnings
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
Genomic Health Reports Continued Double-Digit Growth in Announcement of Second Quarter 2016 Financial Results, Raises Low End of Full-Year Test and Revenue Guidance
August 2, 2016 4:05 PM EDTREDWOOD CITY, Calif., Aug. 2, 2016 /PRNewswire/ --Â Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended June 30, 2016.
Total revenue was $82.0 million in the second quarter of 2016 and includes $0.1 million in contract revenue, compared with $70.6 million in the second quarter of 2015, an increase of 16 percent.
U.S. product revenue was $69.6 million in the second quarter of 2016, an increase of 15 percent, compared with the same period in the prior year. Â Prostate test revenue in the U.S. of $2.3 million contributed to approximately 3 percent of the year-over-year... More

